## Neil C Dunavin

## List of Publications by Citations

Source: https://exaly.com/author-pdf/1864888/neil-c-dunavin-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8 papers 255 a h-index 25-index 25-inde

| # | Paper   | IF   | Citations |
|---|---|------|-----------|
| 8 | Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?. <i>Biomedicines</i> , <b>2017</b> , 5,  | 4.8  | 28        |
| 7 | WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1. <i>Journal of Extracellular Vesicles</i> , <b>2021</b> , 10, e12067   | 16.4 | 14        |
| 6 | A Phase I Study to Evaluate Two Doses of Whartonls Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease. <i>Stem Cell Reviews and Reports</i> , <b>2020</b> , 16, 979-991 | 7.3  | 9         |
| 5 | Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. <i>Hematology/ Oncology and Stem Cell Therapy</i> , <b>2018</b> , 11, 135-141   | 2.7  | 1         |
| 4 | Mesenchymal stromal cell infusions for acute graft-versus-host disease: Rationale, data, and unanswered questions. <i>Advances in Cell and Gene Therapy</i> , <b>2018</b> , 1, e14  | 1.2  | 1         |
| 3 | Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Blood</i> , <b>2018</b> , 132, 832-832              | 2.2  | 1         |
| 2 | Biomarker profiling of steroid-resistant chronic GvHD patients undergoing extracorporeal photopheresis demonstrates high ST2 levels at treatment onset and decline during therapy. <i>Advances in Cell and Gene Therapy</i> , <b>2019</b> , 2, e32        | 1.2  | 1         |
| 1 | LAG3 Promotes Acute Myeloid Leukemia-Induced Immune Suppression. <i>Blood</i> , <b>2018</b> , 132, 2414-2414  | 2.2  |           |